CRL-40,940

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
CRL-40,940
CRL-40,940.svg
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H13F2NO2S
Molar mass309.33 g/mol g·mol−1
3D model (JSmol)

CRL-40,940 (also known as flmodafinil, bisfluoromodafinil and lauflumide) is the bisfluoro analog of modafinil.[1][2][3][4] It is a eugeroic as well as a weak dopamine reuptake inhibitor. Its inventors claim that it is more effective than modafinil and adrafinil, with fewer side effects. It was patented in 2013, and Phase I clinical trials have been underway since December 2015.[5][6][3]

See also[edit]

References[edit]

  1. ^ CA 1199916, Lafon L, "Benzhydrylsulfinylacetamide derivatives", published 28 January 1986 
  2. ^ Cao J, Prisinzano TE, Okunola OM, Kopajtic T, Shook M, Katz JL, Newman AH (October 2010). "Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues". ACS Medicinal Chemistry Letters. 2 (1): 48–52. doi:10.1021/ml1002025. PMC 3041981. PMID 21344069.
  3. ^ a b US 20130295196, Konofal E, "Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereof", published 7 November 2013 
  4. ^ Louis Lafon (18 December 1984). "Patent US 4489095 A - Halogenobenzhydrylsulfinylacetohydroxamic acids". Retrieved 25 July 2015.
  5. ^ "Pipeline". NLS Pharmaceuticals.
  6. ^ "Lauflumide - NLS Pharmaceutics Ltd". Adis Insight. Springer Nature Switzerland AG.